title: Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
abstract: Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and vomiting. This randomized study was designed to evaluate fosaprepitant in polysorbate 80 vehicle for tolerability and bioequivalency to aprepitant. Tolerability was assessed by physical and laboratory examinations and adverse events. Plasma collected for 72 hours was assayed for aprepitant and fosaprepitant. Analysis of variance models were applied to natural log-transformed aprepitant area under the curve (AUC) data. Fosaprepitant up to 150 mg (1 mg/mL) was generally well tolerated. Fosaprepitant 115 mg was AUC bioequivalent to aprepitant 125 mg; the 90% confidence interval for the geometric mean ratio of aprepitant AUC for fosaprepitant 115 mg/aprepitant 125 mg fell within prespecified equivalence bounds of 0.80 to 1.25.
authors.affiliation: Clinical Pharmacology Research Unit, Clinical Pharmacology of Miami, Inc, 550 West 84th Street, Hialeah, FL 33014, USA. kclasseter@gmail.com
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Lasseter
authors.forename: Jay
authors.initials: J
authors.lastname: Gambale
authors.forename: Bo
authors.initials: B
authors.lastname: Jin
authors.forename: Art
authors.initials: A
authors.lastname: Bergman
authors.forename: Marvin
authors.initials: M
authors.lastname: Constanzer
authors.forename: James
authors.initials: J
authors.lastname: Dru
authors.forename: Tae H
authors.initials: TH
authors.lastname: Han
authors.forename: Anup
authors.initials: A
authors.lastname: Majumdar
authors.forename: Judith K
authors.initials: JK
authors.lastname: Evans
authors.forename: M Gail
authors.initials: MG
authors.lastname: Murphy
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D000077608:Aprepitant; D019540:Area Under Curve; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D064729:Neurokinin-1 Receptor Antagonists; D011355:Prodrugs / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency
chemical_list: D000932:Antiemetics; C400262:L 758298; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D011355:Prodrugs; D000077608:Aprepitant; C579707:fosaprepitant